Illumina, LabCorp Ink Multi-Year Deal Zacks.com Last week, ILMN announced plans to enter emerging markets in mid-2014 by launching a human leukocyte antigen (HLA) typing product, developed using its NGS platform. The HLA typing assays that LH will develop based on the NGS platform will enable ... |
